Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Risk parity assigns capital to balance risk contributions across asset classes in retirement portfolios, aiming for steadier, more resilient returns.
26,821 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
When a founder dumps stock, investors naturally pause. This article explains what the Lindblad Expeditions sell after...
The U.S. government is backing quantum startups with billions. Here’s how that move could affect stock selection, ris...
NVIDIA helped turn early bets into life-changing gains. But can it keep delivering millionaire-maker returns? This pr...
A tech-focused investor known for hunting winners, billionaire Philippe Laffont just rotated from a high-profile AI p...
Renowned investor Robert Kiyosaki warns that the market is entering a new phase of risk as liquidity drains from priv...
A major fund stepped in with a bold $30 million wager on Floor & Decor after a sharp 30% decline. This article breaks...
Regulatory moves around AI can move crypto markets faster than a breakthrough in code. This piece explains what happe...
Two tech giants are racing to lead AI-enabled advertising, search, and social platforms. This article analyzes why Al...
Markets wobble, but three names stand out for patient investors. Learn why Microsoft, NVIDIA, and The Trade Desk are ...
When markets get crowded with fast-moving tech stocks, a steady utility ETF can offer ballast. Learn what Vanguard Ut...
June brought a sharp turn for Newmont as gold dynamics and costs collided with production headwinds. This article bre...